{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:59:52Z","timestamp":1783691992807,"version":"3.55.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,20]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>This study aimed to use network pharmacology to investigate the molecular mechanisms and potential targets of naringenin (NR) for nonalcoholic fatty liver disease (NAFLD) treatment to offer new drug development ideas.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The structure and compound information of NR were obtained from PubChem and the traditional Chinese medicine system pharmacology database and analysis platform. The traditional Chinese medicine system pharmacology database and analysis platform Database, Comparative Toxicogenomics Database and Encyclopedia of Traditional Chinese Medicine Database were then used to predict the related targets of NR. Online mendelian inheritance in man, Disgenet, Gene cards, The therapeutic target database and Drug bank were used to screen NAFLD targets, and the intersection analysis was performed with the targets of NR active components to obtain the targets of NR in the treatment of NAFLD. The protein-protein interaction network of therapeutic targets was constructed by protein-protein interaction networks functional enrichment analysis 11.0, and gene ontology (GO) functional enrichment analysis and Kyoto encyclopedia of genes and genomes pathway enrichment analysis of therapeutic targets was performed by Metascape platform.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In this study, 171 NR targets and 1748 potential targets of NAFLD were screened, and 89 crossover targets and 16 core targets were screened and finally obtained. A total of 176 GO items were obtained by GO enrichment analysis (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05), including 389 biological process, 6 cell composition and 30 molecular function. A total of 137 signaling pathways were obtained by Kyoto encyclopedia of genes and genomes pathway enrichment and screening (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). The core targets of NR in the treatment of NAFLD are TP53, CASP3, PRKCA, AKT1, RELA, PPARG, NCOA2, CYP1A1, ESR1, MAPK3, STAT3, JAK1, MAPK1, TNF, PPARA and PRKCB. Enrichment analysis showed that NR mainly involved in biological processes such as cellular response to nitrogen compound, regulation of miRNA transcription and negative regulation of miRNA-mediated gene silencing. It regulates Hepatitis B, Lipid and atherosclerosis, cytomegalovirus infection, Hepatitis C, AGE-RAGE signaling pathway in diabetic patients complications and other ways play a role in the treatment of NAFLD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The therapeutic effect of NR on NAFLD has the characteristics of multi-targets and multi-pathways, which provides a preliminary theoretical basis for clinical trials and the development of new drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035460","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T15:22:35Z","timestamp":1697815355000},"page":"e35460","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Exploration of potential targets and mechanisms of naringenin in the treatment of nonalcoholic fatty liver disease through network pharmacology"],"prefix":"10.1097","volume":"102","author":[{"given":"Chenyang","family":"Yu","sequence":"first","affiliation":[{"name":"First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan","family":"Han","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfang","family":"Yu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhu","sequence":"additional","affiliation":[{"name":"First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyan","family":"Zhu","sequence":"additional","affiliation":[{"name":"First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fule","family":"Wang","sequence":"additional","affiliation":[{"name":"First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0765-4180","authenticated-orcid":false,"given":"Tiefeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease.","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet (London, England)"},{"key":"R2-20250504","first-page":"2270","article-title":"Expert consensus on TCM diagnosis and treatment of nonalcoholic fatty liver disease (2017).","volume":"33","author":"Zhang","year":"2017","journal-title":"J Clin Hepatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2784537","DOI":"10.1155\/2018\/2784537","article-title":"Nonalcoholic fatty liver disease cirrhosis: a review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis.","volume":"2018","author":"Li","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030.","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1016\/j.cgh.2021.12.015","article-title":"Prevalence of high and moderate risk nonalcoholic fatty liver disease among adults in the United States, 1999\u20132016.","volume":"20","author":"Golabi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R6-20250504","first-page":"136","article-title":"Recent advance in the treatment of non-alcoholic fatty liver disease.","volume":"31","author":"Ni","year":"2022","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1002916","DOI":"10.3389\/fendo.2022.1002916","article-title":"Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment.","volume":"13","author":"Che","year":"2022","journal-title":"Front Endocrinol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1194\/jlr.M081935","article-title":"FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.","volume":"59","author":"Papazyan","year":"2018","journal-title":"J Lipid Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis.","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 Agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease.","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci Rep"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial.","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"R12-20250504","first-page":"11","article-title":"Research advance of PPAR\u03b1\/\u03b3 dual agonists.","volume":"23","author":"Zeng","year":"2011","journal-title":"Strait Pharma J"},{"key":"R13-20250504","first-page":"3069","article-title":"An apoptosis signal regulates kinase 1 inhibitor: selonsertib.","volume":"33","author":"Wang","year":"2018","journal-title":"Drugs Clinic"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"173976","DOI":"10.1016\/j.ejphar.2021.173976","article-title":"Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease.","volume":"898","author":"Zhou","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"R15-20250504","first-page":"1382","article-title":"Recent research progress of naringenin.","volume":"24","author":"Ji","year":"2015","journal-title":"Chin J New Drugs"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/1440-1681.12230","article-title":"Naringenin attenuates CCl4 -induced hepatic inflammation by the activation of an Nrf2-mediated pathway in rats.","volume":"41","author":"Esmaeili","year":"2014","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/advances\/nmaa106","article-title":"A comprehensive systematic review of the effects of naringenin, a citrus-derived flavonoid, on risk factors for nonalcoholic fatty liver disease.","volume":"12","author":"Naeini","year":"2021","journal-title":"Adv Nutr"},{"key":"R18-20250504","first-page":"5083","article-title":"Research progress on molecular mechanism of traditional Chinese medicine against non-alcoholic fatty liver disease.","volume":"51","author":"Qian","year":"2020","journal-title":"Chin Tradit Herbal Drugs"},{"key":"R19-20250504","first-page":"412","article-title":"Network pharmacology \u2013 a new technology for the research and development of traditional Chinese medicine.","volume":"18","author":"Ma","year":"2023","journal-title":"World Chin Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"D400","DOI":"10.1093\/nar\/gkr1132","article-title":"PubChem\u2019s Bio assay database.","volume":"40","author":"Wang","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1758-2946-6-13","article-title":"TCMSP: a database of systems pharmacology for drug discovery from herbal medicines.","volume":"6","author":"Ru","year":"2014","journal-title":"J Cheminf"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"W32","DOI":"10.1093\/nar\/gku293","article-title":"Swiss target prediction: a web server for target prediction of bioactive small molecules.","volume":"42","author":"Gfeller","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"D1257","DOI":"10.1093\/nar\/gkac833","article-title":"Comparative toxicogenomics database (CTD): update 2023.","volume":"51","author":"Davis","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"D976","DOI":"10.1093\/nar\/gky987","article-title":"ETCM: an encyclopaedia of traditional Chinese medicine.","volume":"47","author":"Xu","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","article-title":"UniProt: the Universal Protein Knowledgebase in 2023.","volume":"51","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"R26-20250504","first-page":"1.2.1","article-title":"Searching online mendelian inheritance in man (OMIM): a knowledgebase of human genes and genetic phenotypes.","volume":"58","author":"Amberger","year":"2017","journal-title":"Curr Protoc Bioinformatics"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"D833","DOI":"10.1093\/nar\/gkw943","article-title":"DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants.","volume":"45","author":"Pi\u00f1ero","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The Gene cards suite: from gene data mining to disease genome sequence analyses.","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr Protoco Bioinformatics"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"D1398","DOI":"10.1093\/nar\/gkab953","article-title":"Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents.","volume":"50","author":"Zhou","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"Drug bank 5.0: a major update to the drug bank database for 2018.","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"758131","DOI":"10.3389\/fgene.2021.758131","article-title":"Protein function prediction based on PPI networks: network reconstruction vs edge enrichment.","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Genet"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets.","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks.","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"139","DOI":"10.12688\/f1000research.4477.1","article-title":"Biological network analysis with CentiScaPe: centralities and experimental dataset integration.","volume":"3","author":"Scardoni","year":"2014","journal-title":"F1000Research"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metab Clin Exp"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease.","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology"},{"key":"R38-20250504","first-page":"463","article-title":"Role of lipotoxicity in the development and progression of nonalcoholic fatty liver disease.","volume":"37","author":"Zhang","year":"2021","journal-title":"J Clin Hepatol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-1-4419-9072-3_22","article-title":"A paradigm for gene regulation: inflammation, NF-kappaB and PPAR.","volume":"544","author":"Vanden Berghe","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.11569\/wcjd.v27.i19.1171","article-title":"From \u201ctwo hit theory\u201d to\u201dmultiple hit theory\u201d: lmplications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease.","volume":"27","author":"Liu","year":"2019","journal-title":"World Chin J Digestol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy.","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"R42-20250504","first-page":"21","article-title":"Progress on the effects and mechanisms of Farnesoid X receptor on non-alcoholic fattv liver disease.","volume":"11","author":"Huang","year":"2019","journal-title":"Chin J Liver Dis(Electronic Version)"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1463-1326.2008.00869.x","article-title":"Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation.","volume":"10","author":"Ortiz-Andrade","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"R45-20250504","first-page":"1487","article-title":"Absorption kinetics of naringenin in rat intestines.","volume":"34","author":"Ma","year":"2012","journal-title":"Chin Tradit Patent Med"},{"key":"R46-20250504","first-page":"743","article-title":"Mechanisms of the ameliorative effect of naringenin on the diabetic cardiomyopathy: research progress.","volume":"45","author":"Li","year":"2018","journal-title":"J Int Pharm Res"},{"key":"R47-20250504","first-page":"358","article-title":"Research progress on naringenin\u2019s neuroprotective effect.","volume":"23","author":"Wang","year":"2020","journal-title":"Chin J Pract Nervous Dis"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3748\/wjg.v24.i16.1679","article-title":"Beneficial effects of naringenin in liver diseases: molecular mechanisms.","volume":"24","author":"Hern\u00e1ndez-Aquino","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MEG.0000000000002323","article-title":"Effects of naringenin supplementation on cardiovascular risk factors in overweight\/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial.","volume":"34","author":"Naeini","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R50-20250504","first-page":"8","article-title":"Cellulose nanocrystals as carriers for hydrophobic naringenin to enhance its anti-oxidation activity.","volume":"38","author":"Liu","year":"2019","journal-title":"China Pulp Paper"},{"key":"R51-20250504","first-page":"1923","article-title":"Research progress on pharmacological effects of naringenin nanoparticles.","volume":"35","author":"Wang","year":"2020","journal-title":"Drugs Clinic"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.14902","article-title":"Maternal nicotine exposure aggravates metabolic associated fatty liver disease via PI3K\/Akt signaling in adult offspring mice.","volume":"41","author":"Huang","year":"2021","journal-title":"Liver Int"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1111\/jcmm.14293","article-title":"Aucubin inhibited lipid accumulation and oxidative stress via Nrf2\/HO-1 and AMPK signalling pathways.","volume":"23","author":"Shen","year":"2019","journal-title":"J Cell Mol Med"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s13023-021-01929-8","article-title":"A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.","volume":"16","author":"Canaud","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/15548627.2015.1135282","article-title":"MAPK1\/3 regulate hepatic lipid metabolism via ATG7-dependent autophagy.","volume":"12","author":"Xiao","year":"2016","journal-title":"Autophagy"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1194\/jlr.M800297-JLR200","article-title":"Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor.","volume":"49","author":"Allister","year":"2008","journal-title":"J Lipid Res"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3892\/mmr.2016.5966","article-title":"Inhibition of JNK suppresses autophagy and attenuates insulin resistance in a rat model of nonalcoholic fatty liver disease.","volume":"15","author":"Yan","year":"2017","journal-title":"Mol Med Rep"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"e980184","DOI":"10.4161\/23723556.2014.980184","article-title":"HIF-1 suppresses lipid catabolism to promote cancer progression.","volume":"2","author":"Zhang","year":"2015","journal-title":"Mol Cell Oncol"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41574-018-0096-z","article-title":"The role of hypoxia-inducible factors in metabolic diseases.","volume":"15","author":"Gonzalez","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/bph.14938","article-title":"Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3\/NF-\u03baB pathway in mice.","volume":"177","author":"Wang","year":"2020","journal-title":"Br J Pharmacol"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"153412","DOI":"10.1016\/j.phymed.2020.153412","article-title":"Naringenin alleviates nonalcoholic steatohepatitis in middle-aged Apoe(-\/-)mice: role of SIRT1.","volume":"81","author":"Hua","year":"2021","journal-title":"Phytomedicine"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:29:17Z","timestamp":1746325757000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":61,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035460","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]}}}